tiprankstipranks
Trending News
More News >
Dynavax Technologies Corp. (DVAX)
NASDAQ:DVAX
US Market
Advertisement

Dynavax (DVAX) Drug Pipeline

Compare
2,454 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Rf1v-1018
Prevention Of Pneumonic Plague Resulting From Aerosol Exposure To Yersenia Pestis
Phase II
Recruiting
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Oct 02, 2025
Rf1v-1018, Rf1v Vaccine
Vaccine-Preventable Diseases, Plague, Pneumonic, Plague
Phase II
Completed
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
Aug 10, 2022

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Dynavax Technologies Corp. (DVAX) have in its pipeline
      DVAX is currently developing the following drugs: Rf1v-1018, Rf1v-1018, Rf1v Vaccine. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis